Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Search Results

Refine Your Search

By Sector
Sort by: Date|Relevance

Thucydides Trap and gold

When an emerging power attempts to supplant a hegemonic power in international politics, major conflict often ensues. This is the definition of “The Thucydides Trap” as explained in a recent op-ed piece in The Japan Times . The Thucydides Trap (pron...
Richard (Rick) Mills | June 14, 2019 |

Bringing the World Closer With a Language App

Hello Pal is a social mobile messaging app that surpasses the language learning barrier and be communicating with anyone around the world within minutes. You start searching out people to learn a language, and talk in a language that you&CloseCurlyQuo...
BTV-Business Television | June 9, 2018 |

Investors Run From Stocks At Record Pace

BIGGEST WITHDRAWALS ON RECORD There is a lot of relevant information in the text below from a Wall Street Journal article dated December 8, 2019 : “Investors have pulled $135.5 billion from U.S. stock-focused mutual funds and exchange-traded funds so far this year, th...
Chris Ciovacco | December 10, 2019 |

A psychedelic renaissance

Fifty-three years after LSD was banned by the FDA, psychedelic drugs are making a comeback. Only instead of being the pills, mushrooms and acid tabs that helped college students to “turn on, tune in, drop out” Timothy Leary-style, today’...
Richard (Rick) Mills | December 3, 2019 |

Fund Manager Reveals His Top Ten Precious Metals List

Streetwise Reports: Ralph, gold has been trading within a relatively narrow range around $1,300 over the last several months. What's your outlook for the metal? Ralph Aldis: Longer term, I do think we're going to see a higher gold price. As for the near-term factors...
Streetwise Reports | May 10, 2019 |

Is the Fed Gearing Up for a New Round of Quantitative Easing? Here Are the Possible Signs

“This is not QE. In no sense is this QE.” That was Jerome Powell in early October, answering a reporter’s question on whether the Federal Reserve’s intervention in the overnight U.S. repo market constituted anoth...
Frank Holmes | December 11, 2019 |

Where to Get Income in a Low-Yield World

So far in 2020, the yield on the 10-year Treasury has averaged an anemic 0.01 percent when adjusted for inflation. Since the end of January, it’s actually dipped below 0 percent, trading as low as negative 0.14 percent on January 31. What this means is...
Frank Holmes | February 18, 2020 |

Axsome Therapeutics Shares Open 82% Higher on Phase 3 MDD Trial Outcome

Axsome Therapeutics shares reached a new 52-week high price today after the company reported that its AXS-05 drug achieved primary endpoint in the GEMINI Phase 3 trial in Major Depressive Disorder. The firm indicated that the positive results support a New Drug Application fil...
Streetwise Reports | December 17, 2019 |

Exelixis Shares Climb 21% on Positive Phase 3 Advanced Kidney Cancer Study Results

Shares of Exelixis reached a new 52-week high price after the firm reported positive topline results from its Pivotal Phase 3 CheckMate -9ER trial evaluating Opdivo® (nivolumab) in combination with CABOMETYX® (cabozantinib) in previously untreated advanced ...
Streetwise Reports | April 21, 2020 |

Rare Equity Fund Outflows

STOCK PERFORMANCE FOLLOWING SIMILAR MOVES Retail investors have erred on the side of caution in 2019. From a recent MarketWatch article: Analysts said the “extremely cautious stance” of retail investors this year had been puzzling and acted as a...
Chris Ciovacco | December 3, 2019 |
1 2 3 4 5 6 7 8